Facebook
Twitter
LinkedIn
Forward
Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning.
|
Obesity Medicine 2023 - Spring Obesity Summit
|
This webinar re-playing the popular session from the Obesity Medicine Conference 2021 provides a brief overview of FDA-approved anti-obesity medications (AOM’s).
|
Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
|
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
Obesity is a metabolic disease that requires lifelong lifestyle changes and in many patients who are overweight or obese, prescription medication.
|
Dr. Weber will present and discuss case examples that will increase familiarity with antiobesity medication indications, contraindications, side effect profiles, and medication interactions.
|
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|